EMA issues positive opinion on Novo Nordisk's higher-dose Wegovy, supported by strong weight-loss data and ongoing reviews in ...

Novo Nordisk has the potential to maintain more consistent revenue growth throughout next year. There is an indication that the company's pipeline candidates will see strong progress in 2026. Novo ...

Novo Nordisk A/S advances metabolic and rare disease treatments through global research, manufacturing, and clinical ...

(Reuters) -Studies from Novo Nordisk due early next month will give the strongest indication yet of whether blockbuster GLP-1 drugs - a class being used by millions for diabetes and weight loss - can ...

Novo trials test Rybelsus for Alzheimer's cognitive decline Experts uncertain on GLP-1 impact on Alzheimer's brain pathology Success could boost Novo shares by up to 10%, analysts say Nov 20 (Reuters) ...